Tags

Type your tag names separated by a space and hit enter

Ex vivo Skin Permeation Evaluation of An Innovative Transdermal Vehicle Using Nimesulide and Piroxicam as Model Drugs.
Curr Drug Deliv 2017; 14(4):516-520CD

Abstract

BACKGROUND

The transdermal dosage forms presented a limited usage for a long time, for it was believed that the stratum corneum, the outermost layer of epidermis, made it impracticable the permeation of medications through the skin. Studies exploring this area came up with strategies to overcome this barrier; for example, creating a transdermal vehicle to facilitate the drug absorption.

OBJECTIVE

This study aimed to evaluate a new transdermal vehicle through the comparison of its permeation profile and the profile of commercial products, using nimesulide and piroxicam, non steroidal anti-inflammatory drugs.

METHODS

Four different products were evaluated: nimesulide and piroxicam compounded with the new vehicle (emulsion) and commercial nimesulide and piroxicam gels. Ex vivo permeation experiments using Franz-type diffusion cell equipment were conducted, using human skin as membrane. For evaluation of permeated active pharmaceutical ingredients concentrations, we performed quantification from the receptor solution, stratum corneum and viable epidermis + dermis, through high-performance liquid chromatography analyses.

RESULTS

The new vehicle promoted increased permeation of active pharmaceutical ingredients through the viable epidermis and dermis, when compared to commercial products, but the stratum corrneum continued to keep the highest retention.

CONCLUSION

The innovative vehicle was capable of enhancing the transdermal absorption of active pharmaceutical ingredients from the compounded formulations, thus, demonstrating the capability thereof to improve the permeability of active pharmaceutical ingredients by transdermal use.

Authors+Show Affiliations

Faculdade de Ciências Médicas e da Saúde de Juiz de Fora (SUPREMA), Juiz de Fora, MG, Brazil.Faculdade de Ciências Médicas e da Saúde de Juiz de Fora (SUPREMA), Juiz de Fora, MG, Brazil.Ortofarma - Laboratório de Controle de Qualidade, Matias Barbosa, MG, Brazil.Nucleo de Pesquisa e Inovacao em Ciencias da Saude (NUPICS), Federal University of Juiz de Fora (UFJF), Juiz de Fora, MG, Brazil.Nucleo de Pesquisa e Inovacao em Ciencias da Saude (NUPICS), Federal University of Juiz de Fora (UFJF), Juiz de Fora, MG, Brazil.Faculdade de Ciências Médicas e da Saúde de Juiz de Fora (SUPREMA), Juiz de Fora, Brazil.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27557671

Citation

Pereira, Rafaela de Oliveira, et al. "Ex Vivo Skin Permeation Evaluation of an Innovative Transdermal Vehicle Using Nimesulide and Piroxicam as Model Drugs." Current Drug Delivery, vol. 14, no. 4, 2017, pp. 516-520.
Pereira RO, Pelisson E Silva TCC, de Oliveira Ferreira A, et al. Ex vivo Skin Permeation Evaluation of An Innovative Transdermal Vehicle Using Nimesulide and Piroxicam as Model Drugs. Curr Drug Deliv. 2017;14(4):516-520.
Pereira, R. O., Pelisson E Silva, T. C. C., de Oliveira Ferreira, A., Brandao, M. A. F., Raposo, N. R. B., & Polonini, H. C. (2017). Ex vivo Skin Permeation Evaluation of An Innovative Transdermal Vehicle Using Nimesulide and Piroxicam as Model Drugs. Current Drug Delivery, 14(4), pp. 516-520. doi:10.2174/1567201813666160824142013.
Pereira RO, et al. Ex Vivo Skin Permeation Evaluation of an Innovative Transdermal Vehicle Using Nimesulide and Piroxicam as Model Drugs. Curr Drug Deliv. 2017;14(4):516-520. PubMed PMID: 27557671.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ex vivo Skin Permeation Evaluation of An Innovative Transdermal Vehicle Using Nimesulide and Piroxicam as Model Drugs. AU - Pereira,Rafaela de Oliveira, AU - Pelisson E Silva,Taize Carla Costa, AU - de Oliveira Ferreira,Anderson, AU - Brandao,Marcos Antonio Fernandes, AU - Raposo,Nadia Rezende Barbosa, AU - Polonini,Hudson Caetano, PY - 2016/05/17/received PY - 2016/06/30/revised PY - 2016/07/29/accepted PY - 2016/8/26/pubmed PY - 2018/5/8/medline PY - 2016/8/26/entrez KW - NSAIDS KW - Nimesulide KW - permeation studies KW - piroxicam KW - stratum corneum KW - transdermal vehicle KW - viable epidermis SP - 516 EP - 520 JF - Current drug delivery JO - Curr Drug Deliv VL - 14 IS - 4 N2 - BACKGROUND: The transdermal dosage forms presented a limited usage for a long time, for it was believed that the stratum corneum, the outermost layer of epidermis, made it impracticable the permeation of medications through the skin. Studies exploring this area came up with strategies to overcome this barrier; for example, creating a transdermal vehicle to facilitate the drug absorption. OBJECTIVE: This study aimed to evaluate a new transdermal vehicle through the comparison of its permeation profile and the profile of commercial products, using nimesulide and piroxicam, non steroidal anti-inflammatory drugs. METHODS: Four different products were evaluated: nimesulide and piroxicam compounded with the new vehicle (emulsion) and commercial nimesulide and piroxicam gels. Ex vivo permeation experiments using Franz-type diffusion cell equipment were conducted, using human skin as membrane. For evaluation of permeated active pharmaceutical ingredients concentrations, we performed quantification from the receptor solution, stratum corneum and viable epidermis + dermis, through high-performance liquid chromatography analyses. RESULTS: The new vehicle promoted increased permeation of active pharmaceutical ingredients through the viable epidermis and dermis, when compared to commercial products, but the stratum corrneum continued to keep the highest retention. CONCLUSION: The innovative vehicle was capable of enhancing the transdermal absorption of active pharmaceutical ingredients from the compounded formulations, thus, demonstrating the capability thereof to improve the permeability of active pharmaceutical ingredients by transdermal use. SN - 1875-5704 UR - https://www.unboundmedicine.com/medline/citation/27557671/Ex_vivo_Skin_Permeation_Evaluation_of_An_Innovative_Transdermal_Vehicle_Using_Nimesulide_and_Piroxicam_as_Model_Drugs_ L2 - http://www.eurekaselect.com/145053/article DB - PRIME DP - Unbound Medicine ER -